{"prompt": "['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', '8', 'Study Design', 'This study will be conducted in accordance with applicable laws and regulations including, but', \"not limited to, the ICH E6 guideline 'Note for Good Clinical Practice' (CPMP/ICH/135/95) (2)\", 'based on the principles of the Declaration of Helsinki (3). The study will be duly conducted in', 'compliance with the Medicinal Products Act (Arzneimittelgesetz AMG), (\u00a7\u00a7 40-42) (1). An', 'independent ethics committee and the competent authority must review and approve the study', 'before any patients are enrolled.', '8.1', 'Description of the Study Design', 'This is a multicenter, open-label, single-arm, phase II, pilot study to evaluate the efficacy and', 'safety of apremilast involving approximately 20 patients with PPP. The screening period is up', 'to 4 weeks and treatment takes place over 20 weeks per patient. No follow up period takes', 'place. No extension is planned.', 'Recruitment period is 4 months; hence study duration from FPI to LPO is approx. 9 months.', '4 patients per site are expected to be recruited, assuming enrolment of both genders with', 'distribution according to prevalence of condition. If recruitment is not running as anticipated', 'after 2 months, recruitment will be opened to become competitive.', 'Patient recruitment will take place at approximately 5 sites in Germany. The investigators', 'should have relevant expertise in diagnosing and treating PPP or be specialized in', 'dermatology. Patients will be enrolled until 20 patients are included into the study. Drop-outs', 'will not be replaced.', 'Please refer to the Study Flow Chart in the synopsis for the time schedule of the assessments.', 'Five visits per patients are planned including:', 'Visit 1 at week -4 - -1 (screening)', 'Visit 2 at week 0 (baseline)', 'Visit 3 at week 4', 'Visit 4 at week 12', 'Visit 5 at week 20 (end of study)', 'After completion of participation in the study, patients are advised to follow medical', 'management of their treating physician (see as well Section 10.6.1).', '8.2', 'Study Endpoints', '8.2.1', 'Primary Endpoint(s)', 'Percentage change from baseline in PPPASI after 20 weeks of treatment with', 'apremilast', '8.2.2 Secondary Endpoint(s)', 'Absolute and percent change from baseline in PPPASI during the 20 weeks', 'treatment period', 'Page 25 of 75']['Confidential', 'Prof. Dr. Kristian Reich', 'Clinical Study Protocol', 'APLANTUS 069-008', 'Final 3.0, 07. June 2018', 'PPPASI 50 response and PPPASI 75 response, defined as a 50% and 75%', 'decrease in PPPASI from baseline, during the 20 weeks treatment period', 'DLQI bands (0-1 no effect, 2-5 small effect, 6-10 moderate effect, 11-20 very', 'large effect, 21-30 extremely large effect) during the 20 weeks treatment period', 'Absolute and percent change from baseline in DLQI during the 20 weeks', 'treatment period', 'Safety as assessed by treatment-emergent adverse events (TEAEs), vital signs and', 'physical examination', '8.2.3 Exploratory Endpoints', 'Absolute and percentage change from baseline in level of immunological markers', 'in plasma / serum during the 20 weeks treatment period with apremilast', 'Percentage change from baseline in level of immunological markers in skin', 'biopsy samples after 20 weeks of treatment with apremilast (sub-study)', '8.3', 'Patient Identification', \"Patients will be identified from the investigator's database.\", 'Upon enrolment, each patient will receive a 5 digit patient number (XX-XXX) starting with:', '2 digits for the site', 'separated by hyphen', '3 digits for the patient (ascending order)', 'E.g. 01-001', 'Within each site, the investigator will allocate the patient numbers in ascending order of', 'patients screened and include each screened patient in a screening, enrolment and', 'randomization log with site number, a running patient number and year of birth. All patients will', 'be identified by the unique patient number in a patient identification log in the investigator site', 'file.', 'As this study is an open label, single-arm study no randomization will take place.', 'Patients who drop out will not be replaced.', '8.4', 'Withdrawal of Patients', 'In accordance with the informed consent and the Declaration of Helsinki (3), any patient can', 'refuse to participate or withdraw from the study without giving reasons at any time without any', 'penalty or loss of benefits to which the patient is otherwise entitled. When appropriate, patients', 'may be placed on other conventional therapy when clinically indicated.', 'Patients have to be withdrawn from the study by the investigator if at least one of the following', 'events occurs', 'Withdrawal of informed consent', 'Pregnancy', 'Page 26 of 75']\n\n###\n\n", "completion": "END"}